CHEMED CORP SEC Filings

Chemed Corporation filed a Form 144 reporting proposed sales of Common Stock by an identified holder. The notice lists a proposed block of 1,000 shares through Merrill Lynch with an entry dated 05/01/2026. The filing also records prior stock awards/exercises dated 08/02/2024 (682 shares) and 10/30/2023 (318 shares). Recent sales reported in the past three months list transactions of 1,000, 1,000 and 1,500 shares on 03/12/2026 and 03/27/2026 with corresponding numeric entries shown in the excerpt.

Kevin J. McNamara filed a Form 144 reporting proposed dispositions of Common Stock of CHE. The filing lists sales dated 03/12/2026 (1,000 shares, $404,244.00 and 1,000 shares, $402,050.00) and 03/27/2026 (1,500 shares, $558,855.00).

Chemed Corp Schedule 13G: Vanguard Capital Management reports beneficial ownership of 744,055 shares of Common Stock, representing 5.40% of the class as of 03/31/2026. The filer reports sole voting power over 107,985 shares and sole dispositive power over 744,055 shares.

The filing is signed by Vanguard's Head of Global Fund Administration on 04/29/2026 and describes holdings that include securities held by Vanguard funds and managed accounts.

Vanguard Portfolio Management reported beneficial ownership of 817,550 shares of Chemed Corp common stock, equal to 5.93% of the class. The filer states sole dispositive power over 817,550 shares and sole voting power for 1,851 shares. The filing is signed on 04/29/2026.

Chemed Corporation reported first-quarter 2026 service revenues and sales of $657.5 million, up modestly from $646.9 million a year earlier. Net income was $66.3 million versus $71.8 million, as higher costs and expenses offset revenue growth.

Hospice segment VITAS generated net revenue of $420.0 million, driven by a 2.2% increase in days of care and Medicare rate increases. Roto-Rooter revenue was $237.5 million, slightly below last year, with softer water restoration and contractor activity despite higher pricing in core plumbing and drain services.

The company produced net cash from operating activities of $88.2 million, used $190.0 million to repurchase 500,000 shares, and ended the quarter with $91.2 million of long-term debt under its revolving credit facility and $16.9 million of cash and cash equivalents.

Chemed Corporation reported first-quarter 2026 revenue of $657.5 million, up slightly from $646.9 million a year earlier, with net income of $66.3 million and diluted EPS of $4.84 versus $4.86. Adjusted diluted EPS rose to $5.65 from $5.63.

VITAS revenue grew 3.1% to $420.0 million, driven by 2.2% higher days-of-care and Medicare rate increases, while Roto-Rooter revenue slipped 0.9% to $237.5 million and its adjusted EBITDA margin fell. Chemed bought San Francisco and Fort Worth Roto-Rooter franchises for $20.6 million and repurchased 500,000 shares for $197.7 million.

Management raised full-year 2026 guidance, now expecting adjusted EPS of $24.00–$24.75, whose midpoint is a 13% increase over 2025’s $21.55 and above the prior 2026 range of $23.25–$24.25. VITAS growth and margins were revised upward, while Roto-Rooter’s adjusted EBITDA margin outlook was trimmed due to higher marketing costs.

Chemed Corporation entered into a new five-year $450 million senior secured revolving credit facility, documented in a Sixth Amended and Restated Credit Agreement. The facility includes a $100 million letters of credit sublimit and an accordion feature of up to $250 million in additional revolving capacity.

Borrowings bear interest at a floating rate based on the secured overnight financing rate (SOFR) plus a tiered margin that depends on Chemed’s leverage ratio. JPMorgan Chase Bank serves as Administrative Agent and Joint Lead Arranger, with Bank of America, PNC Bank and U.S. Bank in key syndicate roles.

Chemed Corporation amended its Definitive Proxy Statement to correct the number of shares outstanding: 13,413,917 shares were outstanding and entitled to vote as of March 23, 2026. The amendment is clerical only and makes no other changes to the proxy materials for the Annual Meeting on May 18, 2026.

The Proxy Statement describes the Annual Meeting agenda (elect nine directors; ratify auditors; advisory vote on executive compensation), voting procedures, director nominees and detailed governance and executive compensation policies, including 2025 pay outcomes and equity incentive structures.

Chemed Corporation is asking stockholders to vote at its May 18, 2026 annual meeting on three main items: electing nine directors, ratifying the independent auditor, and approving executive compensation in an advisory vote. Stockholders of record on March 23, 2026, when 14,614,676 shares were outstanding, may vote in person or by mail, phone, or Internet.

The Board uses a majority voting standard in uncontested director elections and all incumbent nominees have pre-submitted resignations if they fail to receive majority support. Non-employee directors receive $80,000 in annual cash retainers plus meeting fees and about $160,394 in fully vested stock awards, with additional retainers for committee roles and the Chair.

For 2025, CEO Kevin J. McNamara’s total compensation was $12.9 million, with roughly 72.9% performance-based. The pay program ties annual bonuses mainly to Adjusted EPS and return on assets, and long-term incentives to three-year cumulative Adjusted EPS and relative Total Shareholder Return versus a defined peer group. In the 2025 say-on-pay vote, 88.63% of shares voting supported Chemed’s executive compensation program.